Spruce Biosciences, Inc.
Spruce Biosciences, Inc. (Nasdaq: SPRB) is a biopharmaceutical company developing therapies for neurological and endocrine disorders with significant unmet medical need. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for MPS IIIB, a rare genetic disease, and is… From the company’s description.
In fiscal 2025, Spruce Biosciences, Inc. reported a net loss of $38.97M. Operations used $33.33M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Spruce Biosciences, Inc. does
In the company’s own words
Spruce Biosciences, Inc. (Nasdaq: SPRB) is a biopharmaceutical company developing therapies for neurological and endocrine disorders with significant unmet medical need. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for MPS IIIB, a rare genetic disease, and is administered directly into the cerebrospinal fluid. The company also develops tildacerfont, an oral CRF1 receptor antagonist studied with the Cortibon genetic selection tool for major depressive disorder, and SPR202, an anti-CRH antibody licensed for congenital adrenal hyperplasia and other indications. Spruce has no commercialized products and is preparing for a potential U.S. regulatory submission for TA-ERT; its MDD study of tildacerfont was discontinued in 2026. It operates as a single biopharmaceutical business, with no reportable operating segments identified in the available business description. Founded in 2016, Spruce expanded its portfolio through a 2024 acquisition of Allievex’s licensed enzyme-replacement therapy programs and a 2025 license for SPR202.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1683553
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Spruce Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Spruce Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Spruce Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Spruce Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Spruce Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”